Synapse - Malin Hultcrantz

Search Within

Malin Lisa Hultcrantz

Results (62)

Dynamics of minimal residual disease in patients with multiple myeloma on continuous lenalidomide maintenance: A single-arm, single-centre, phase 2 trial

Journal Article

Diamond, B.; Korde, N.; Lesokhin, A. M.; Smith, E. L.; Shah, U.; Mailankody, S.; Hultcrantz, M.; Hassoun, H.; Lu, S. X.; Tan, C.; more...
The Lancet Haematology (2021)

Fulltext@MSK | Save

Tailored treatment to MRD response: A phase I/II study for newly diagnosed multiple myeloma patients using high dose twice-weekly carfilzomib (45 and 56 mg/m2) in combination with lenalidomide and dexamethasone

Research Letter

Korde, N.; Mastey, D.; Tavitian, E.; Mailankody, S.; Lesokhin, A.; Hassoun, H.; Smith, E. L.; Lendvai, N.; Hultcrantz, M.; Shah, U.; more...
American Journal of Hematology (2021)

Fulltext@MSK | Save

Initial whole-genome sequencing of plasma cell neoplasms in first responders and recovery workers exposed to the World Trade Center attack of September 11, 2001

Journal Article

Maura, F.; Diamond, B.; Maclachlan, K. H.; Derkach, A.; Yellapantula, V. D.; Rustad, E. H.; Hultcrantz, M.; Shah, U. A.; Hong, J.; Landau, H. J.; more...
Clinical Cancer Research (2021)

Fulltext@MSK | Save

Whole-genome sequencing reveals progressive versus stable myeloma precursor conditions as two distinct entities

Journal Article

Oben, B.; Froyen, G.; Maclachlan, K. H.; Leongamornlert, D.; Abascal, F.; Zheng-Lin, B.; Yellapantula, V.; Derkach, A.; Geerdens, E.; Diamond, B. T.; more...
Nature Communications (2021)

Fulltext@MSK | Save

Routine evaluation of minimal residual disease in myeloma using next-generation sequencing clonality testing: Feasibility, challenges, and direct comparison with high-sensitivity flow cytometry

Journal Article

Ho, C.; Syed, M.; Roshal, M.; Petrova-Drus, K.; Moung, C.; Yao, J.; Quesada, A. E.; Benhamida, J.; Vanderbilt, C.; Liu, Y.; more...
Journal of Molecular Diagnostics (2021)

Fulltext@MSK | Save

Revealing the impact of structural variants in multiple myeloma

Journal Article

Rustad, E. H.; Yellapantula, V. D.; Glodzik, D.; Maclachlan, K. H.; Diamond, B.; Boyle, E. M.; Ashby, C.; Blaney, P.; Gundem, G.; Hultcrantz, M.; more...
Blood Cancer Discovery (2020)

Fulltext@MSK | Save

Whole-genome sequencing reveals evidence of two biologically and clinically distinct entities: Progressive versus stable myeloma precursor disease

Meeting Abstract

Oben, B.; Froyen, G.; Maclachlan, K. H.; Zheng-Lin, B.; Yellapantula, V.; Abascal, F.; Leongamornlert, D. A.; Derkach, A.; Geerdens, E.; Diamond, B.; more...
Blood (2020)

Fulltext@MSK | Save

Copy number signatures predict chromothripsis and poor clinical outcome in newly diagnosed multiple myeloma patients

Meeting Abstract

Maclachlan, K. H.; Zheng-Lin, B.; Yellapantula, V.; Derkach, A.; Rustad, E. H.; Diamond, B.; Hultcrantz, M.; Dogan, A.; Zhang, Y.; Morgan, G.; more...
Blood (2020)

Fulltext@MSK | Save

The genomic complexity of multiple myeloma precursor disease can be predicted using copy number signatures on targeted sequencing and SNP array data

Meeting Abstract

Maclachlan, K. H.; Zheng-Lin, B.; Yellapantula, V.; Rustad, E. H.; Diamond, B.; Hultcrantz, M.; Dogan, A.; Zhang, Y.; Morgan, G.; Landgren, O.; more...
Blood (2020)

Fulltext@MSK | Save

Weekly carfilzomib, lenalidomide, dexamethasone and daratumumab (wKRd-D) combination therapy in newly diagnosed multiple myeloma: final results from a clinical and correlative phase 2 study

Meeting Abstract

Landgren, O.; Hultcrantz, M.; Lesokhin, A. M.; Mailankody, S.; Hassoun, H.; Tan, C.; Shah, U. A.; Lu, S. X.; Diamond, B.; Salcedo, M.; more...
Blood (2020)

Fulltext@MSK | Save